Slowing Tecfidera Sales Increases Biogen's (BIIB) M&A Risk - Moody's

Baird Downgrades Biogen (BIIB) to Neutral; Diminished Growth Prospects

July 27, 2015 6:35 AM EDT

Baird downgraded Biogen (NASDAQ: BIIB) from Outperform to Neutral with a price target of $316.00 (from $480.00), saying lackluster sales and lowered guidance leaves a growth void.

Analyst Brian Skorney commented, "We're aware that this downgrade may be too little, too late given... More

Biogen (BIIB) Trading at 'Pharma-Like' Multiple, Cowen Says

July 24, 2015 1:04 PM EDT

Cowen analyst Eric Schmidt reiterated his Outperform rating and $494 price target on Biogen (NASDAQ: BIIB), with shares down nearly 20% on disappointing Q2 results and outlook. Schmidt maintained his bullish view, saying the stock is trading at a 'pharma-like' multiple.

Schmidt commented,... More

Biogen (BIIB) Worth a 'Hard Look' when Smoke Clears, Stifel Says

July 24, 2015 12:19 PM EDT

Stifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) following disappointing Q2 results, which has shares down 18.4% intra-day. While retaining his Hold rating, the analyst said the stock is worth a hard look when the smoke clears.

Shrader commented, "Biogens numbers were... More

BMO Capital Downgrades Biogen (BIIB) to Market Perform

July 24, 2015 11:42 AM EDT

(Updated - July 24, 2015 11:43 AM EDT)

BMO Capital downgraded Biogen (NASDAQ: BIIB) from Outperform to Market Perform with a price target of $360 (from $511) after the company posted disappointing Q2 results and outlook.

Analyst Jim Birchenough commented, "With more dramatic than expected slowing of TECFIDERA... More

Biogen (BIIB) Tops Q2 EPS by 12c; Cuts FY15 Revenue Growth, EPS Outlook

July 24, 2015 6:50 AM EDT

(Updated - July 24, 2015 6:51 AM EDT)

Biogen (Nasdaq: BIIB) reported Q2 adjusted EPS of $4.22, which was $0.12 better than the analyst estimate of $4.10. Revenue for the quarter came in at $2.59 billion versus the consensus estimate of $2.71 billion.

Neurology Highlights

In April 2015, the U.S. Food and Drug Administration accepted for review the Biologics License Application for ZINBRYTA for the treatment of relapsing forms of multiple sclerosis. ZINBRYTA is being jointly developed by Biogen and... More